Name	Byung Sik Cho
Current Position & Affiliation	Professor & Department of Hematology, Catholic Hematology Hospital, Leukemia Research Center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
Country	Republic of Korea
Major Field	Research in AML: drug development, translational oncology, biomarkers & prognostication, immunotherapy, and stem cell transplantation

Educational Background	
Bachelor's degree	Catholic University of Korea, Seoul, Korea, 1992-1998
Master of Medical Science	Catholic University of Korea, Seoul, Korea, 2006-2008
Doctor of Medical Science	Catholic University of Korea, Seoul, Korea, 2008-2011

Professional Experience	
May.2006 - Feb. 2009	Clinical and Research Fellow Department of Hematology, Catholic Hematopoietic Stem Cell Transplantation Center, St. Mary's Hospital, CUK, Seoul, Korea
Mar. 2009 - Feb. 2010	Clinical Assistant Professor, Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, CUK, Seoul, Korea
Mar. 2010 – Mar. 2013	Assistant Professor, Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, CUK, Seoul, Korea
April. 2013 – 2019	Associate Professor, Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, CUK, Seoul, Korea
April. 2013 – Feb. 2015	Visiting Scholar, Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Oct. 2015 – Sep 2021	Adjunct Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
April. 2019 –Present	Professor, Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, CUK, Seoul, Korea
Oct. 2021 – 2024	Adjunct Professor, Department of Leukemia, The University of Texas MD Anderson

Cancer Center, Houston, TX, USA

Other Experience and Professional Memberships

Member of Korean Medical Association
Member of Korean Society of Internal Medicine
Member of Korean Society of Hematology: Special director of KSH (since 2022),
Member of Korean Society of Hematopoietic Stem Cell Transplantation: academic director (2021-2023)
Member of Korean Society of Hematopoietic Stem Cell Transplantation: secretary general (2023-2025)
Member of Korean Society of Hematology: Special director of KSH (since 2022)

Main Scientific Publications

*** As a first or corresponding author for a recent five years**

1. Kwag D, **Cho BS**, Park S, Kim HJ. Objectively measured physical function predicts mortality in older adults with acute myeloid leukemia treated by lower-intensity therapy: A prospective cohort study. **J Geriatr Oncol. 2025 Aug 9;16(8):102335.**
2. Kim YJ, Kwag D, Kim BR, Son H, Park S, Kim HJ, **Cho BS**. Characterization of the Bone Marrow Lymphoid Microenvironment and Discovery of Prognostic Immune-Related Factors in Acute Myeloid Leukemia. **Int J Mol Sci. 2024 Dec 4;25(23):13039.**
3. Min GJ, **Cho BS**, Kwag D, et al. Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML. **Front Oncol. 2023 Nov 7;13:1281782**.
4. Park S, Kim TY, **Cho BS**, et al. Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia. **Haematologica. 2024 Apr 1;109(4):1095-1106.**
5. Jung J, Kwag D, ---, **Cho BS,** Kim M, et al. Perspectives on acute myeloid leukemia diagnosis: a comparative analysis of the latest World Health Organization and the International Consensus Classifications. **Leukemia. 2023;37(10):2125-2128.**
6. Kuen DS, Hong J, ---, **Cho BS**, Kim BS, Chung Y, et al. A personalized cancer vaccine that induces synergistic innate and adaptive immune responses. **Adv Mater. 2023 Sep;35(36):e2303080.**
7. Kim HS, Kim BR, D, ---, **Cho BS**, Park S, et al. TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently. **Blood Adv. 2023 Jul 11;7(13):3155-3168**
8. Lee JH, Cho BS, Kwag D, et al. Haploidentical versus Double-Cord Blood Stem Cells as a Second Transplantation for Relapsed Acute Myeloid Leukemia. **Cancers (Basel). 2023 Jan 10;15(2):454.**
9. Kwag D, **Cho BS**, Bang SY, et al. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. **Blood Cancer J. 2022 Dec 19;12(12):169.**
10. Min GJ, **Cho BS**, Park SS, et al. Geriatric assessment predicts non-fatal toxicities and survival for intensively treated older adults with AML. **Blood. 2022 Mar 17;139(11):1646-1658**
11. **Cho BS**, Min GJ, Park SS, et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. **Am J Hematol. 2021 Nov 1;96(11):1441-1449.**

12. **Cho BS**, Min GJ, Park SS, et al. Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11. **Bone Marrow Transplant. 2021 Nov;56(11):2682-2689.**
13. Kim HJ, Kim Y, ---, **Cho BS,** et al. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. **Blood Cancer J. 2021 Jun 4;11(6):109.**
14. **Cho BS,** Yahng SA, Min GJ, et al. Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients. **Transplant Cell Ther. 2021 Sep;27(9):774.e1-774.e12.**
15. **Cho BS**, Min GJ, Park SS, et al. Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1-RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1-RUNX1T1. **Cancers (Basel). 2021 Jan 18;13(2):E336.**
16. **Cho BS,** Min GJ, Park S, et al. Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study. **Am J Hematol. 2021 Jan;96(1):98-109.**